Camille Samuels, Venrock

Camille Samuels, Venrock

Camille Samuels is partner of Venrock.

John Jorden, Amgen

John Jorden, Amgen

John Jorden is executive director, Amgen Digital Health at Amgen.

Jay Appel, Bristol-Myers Squibb

Jay Appel, Bristol-Myers Squibb

Jay Appel is executive director of Bristol-Myers Squibb.

Interview | Hans Kaspersetz, Arteric

Interview | Hans Kaspersetz, Arteric

Is technology causing agencies to become more specialized? Is there still a need for the human connection?

Five things for pharma marketers to know: Wednesday, January 24, 2018

Five things for pharma marketers to know: Wednesday, January 24, 2018

Novartis sees single-digit growth with new CEO; J&J takes $13.6b charge in the wake of the new tax law; New York City invests in biotech

Five things for pharma marketers to know: Wednesday, January 17, 2018

Five things for pharma marketers to know: Wednesday, January 17, 2018

Celgene reportedly in talks to buy Juno; Novartis' Kymriah receives fast-track reviews in U.S. and Europe; BI's Gilotrif gets expanded approval in lung cancer

Five things for pharma marketers to know: Friday, January 12, 2018

Five things for pharma marketers to know: Friday, January 12, 2018

Pharma looks to Spark for pricing blueprint; Ipsen hires Amgen exec as CEO of North America; FDA could improve social-media approach, study finds

Five things for pharma marketers to know: Tuesday, January 9, 2018

Five things for pharma marketers to know: Tuesday, January 9, 2018

Shire considers splitting into two units; New Jersey finalizes physician-pharma gift limit; more biotech M&As expected in 2018

Five things for pharma marketers to know: Monday, January 8, 2018

Five things for pharma marketers to know: Monday, January 8, 2018

Celgene to buy Impact Biomedicines for up to $7 billion; Pfizer plans to cut 300 positions in neuroscience; Perrigo hires new CEO

Five things for pharma marketers to know: Friday, January 5, 2018

Five things for pharma marketers to know: Friday, January 5, 2018

Takeda announces deals worth more than $1 billion; biotech and pharma investments reached $10.5 billion in 2017; prescriptions for nerve pain on the rise